The global ADHD therapeutics market is expected to reach US$ 64,742.37 billion in 2030 from US$ 28,594.55 billion in 2022. The market is estimated to grow with a CAGR of 10.8% from 2022 to 2030.
Key factors driving the ADHD therapeutics market growth are the growing prevalence of ADHD, increasing patient awareness and treatment-seeking behavior, and rising emphasis on research and development of ADHD therapeutics. However, the side effects associated with ADHD medications and their limited symptomatic relief hinder the market growth.
Market Drivers of the ADHD Therapeutics Market
Prevalence of ADHD and Rising Emphasis on Research and Development of ADHD Therapeutics.
As per the article published by the Centers for Disease Control and Prevention (CDC), in February 2022, approximately 6 million children aged 3-17 years in the US were diagnosed with ADHD, accounting for 9.8% of the population between 2016 and 2019. Additionally, according to an article published by PubMed Central in 2022, ADHD affects 5-7.2% of children and 2.5-6.7% of adults worldwide. According to recent estimates, the frequency of adolescents in the US is much greater, at roughly 8.7% or 5.3 million. Although it has traditionally been thought of as a childhood condition, up to 90% of children with ADHD continue to have symptoms in adulthood. It is also possible to diagnose in adults because 75% of individuals with ADHD were not previously diagnosed during childhood, according to a research study. ADHD is frequently associated with comorbid conditions such as anxiety, depression, learning disorders, and substance abuse. The presence of these comorbidities increases the treatment complexity, necessitating a multi-dimensional approach that addresses both ADHD symptoms and associated conditions. Drugs such as psychostimulants and non-stimulants are recommended, which can assist children in managing their ADHD symptoms in their daily lives and can help regulate behaviors that may cause difficulties in various aspects of their lives, including personal life and academic performance. Therefore, the increasing prevalence of ADHD, combined with the increased demand for drugs for treatment, is propelling the market.
Furthermore, the market for ADHD therapeutics is expected to grow due to continuous developments in medical treatments, an increase in neuroscience research projects, and a rise in public awareness about mental illnesses. Growing awareness among patients, caregivers, and healthcare professionals about the impact of ADHD on daily functioning has led to an increased willingness to seek effective therapeutic interventions. The rising number of people suffering from various mental health disorders, including ADHD, has drawn the attention of governments worldwide, prompting them to take action. Biotechnology and pharmaceutical companies also focus on creating innovative treatments for ADHD. According to Regional Development Australia, in July 2021, the New South Wales (NSW) government contributed US$ 1.8 million to the ADHD pilot program for 2021-2022, with a total investment of US$ 7.7 million over four years to trial a new model of care and management for children with behavioral issues, including ADHD.
Opportunities in the ADHD Therapeutics Market
The continuous development of novel pharmacological drugs, including non-stimulants, presents opportunities for combating ADHD, addressing emerging adverse reactions, and expanding the armamentarium of treatment options. Additionally, collaborative initiatives among healthcare institutions, pharmaceutical companies, and research organizations present opportunities for discovering novel therapeutic targets that drive innovation, accelerate clinical trials, and improve access to ADHD therapeutics and support services.
ADHD Therapeutics Market: Segmental Overview
The ADHD therapeutics market, by drug type, is bifurcated into stimulant and non-stimulant drugs. The stimulant drugs segment held a larger market share in 2022 and is anticipated to register a higher CAGR during 2022-2030.
The ADHD therapeutics market, by age group, is segmented into pediatric & adolescent, and adult. The pediatric & adolescent segment held the largest market share in 2022. The adult segment is anticipated to register the highest CAGR from 2022 to 2030.
The ADHD therapeutics market, by distribution channel, is segmented into hospital pharmacies, retail pharmacies, and e-commerce. In 2022, the hospital pharmacies segment held the largest market share and is anticipated to register the highest CAGR during 2022-2030.
ADHD Therapeutics Market: Geographical Overview
Asia Pacific is the fastest-growing market for ADHD owing to key regional players and several strategic initiatives undertaken to develop and market new products. For example, in June 2020, Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization, Inc. reported positive results from its two six-week phase 3 clinical trials that assessed the effectiveness, safety, and tolerability of oral centanafadine. Centanafadine is a new experimental drug designed to treat adult patients diagnosed with ADHD. The company also planned to study the effects of centanafadine in children with ADHD and to discuss the next steps with the US Food and Drug Administration.
In 2022, North America held the largest share of the global ADHD therapeutics market size. In the region, the US held the largest ADHD therapeutics market share in 2022 and is estimated to continue its dominance from 2022 to 2030. The US has a high prevalence of ADHD, which propels the ADHD therapeutics market growth. According to Cingulate, ~6.4 million children and adolescents between 4 and 17 years of age were diagnosed with ADHD in 2022. Among them, over 80% of this group receive treatment, and about 65% experience ongoing symptoms of ADHD into adulthood. Additionally, improved patient affordability, favorable reimbursement policies, and increased awareness of current drugs are expected to drive market growth.